These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26616890)

  • 41. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions.
    Adachi A; Nagai H; Horikawa T
    Dermatology; 2007; 214(1):85-8. PubMed ID: 17191054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Dermatomycosis caused by Tricophyton rubrum simulating lupus erythematosus tumidus].
    de Graciansky P; Grupper C; Sirkis L
    Bull Soc Fr Dermatol Syphiligr; 1965; 72(6):809-11. PubMed ID: 5881955
    [No Abstract]   [Full Text] [Related]  

  • 43. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 44. [Lymphocytic infiltration of the skin (Jessner)].
    Jaqueti G; Ballesteros N; Gonzalez P; Corripio F
    Actas Dermosifiliogr; 1966; 57(9):279-86. PubMed ID: 5975622
    [No Abstract]   [Full Text] [Related]  

  • 45. Inverse psoriasis treated with ustekinumab.
    Campos MA; Varela P; Baptista A; Moreira AI
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27222277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphocytic infiltration of the skin (Jessner-Kanof) but not reticular erythematous mucinosis occasionally represents clinical manifestations of Borrelia-associated pseudolymphoma.
    Ziemer M; Eisendle K; Müller H; Zelger B
    Br J Dermatol; 2009 Sep; 161(3):583-90. PubMed ID: 19486001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab.
    Goh SW; Jamil A; Nor NM; Cader RA; Shaharir SS
    Indian J Dermatol Venereol Leprol; 2020; 86(1):68-70. PubMed ID: 31823905
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunohistochemical studies in lymphocytic infiltration of the skin (Jessner) and discoid lupus erythematosus. A comparative study.
    Willemze R; Vermeer BJ; Meijer CJ
    J Am Acad Dermatol; 1984 Nov; 11(5 Pt 1):832-40. PubMed ID: 6392362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis].
    Amy de la Bretèque M; Appere-De Vecchi C; Zeboulon C; Zaien I; Sigal ML; Mahé E
    Ann Dermatol Venereol; 2015 Mar; 142(3):193-6. PubMed ID: 25624139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
    Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
    Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
    [No Abstract]   [Full Text] [Related]  

  • 51. Chronic discoid lupus erythematosus with chloroquine retinopathy.
    McCarthy JT
    Arch Dermatol; 1971 Jul; 104(1):109-10. PubMed ID: 4256261
    [No Abstract]   [Full Text] [Related]  

  • 52. Subacute-cutaneous lupus erythematosus induced by Simvastatin.
    Rüger RD; Simon JC; Treudler R
    J Dtsch Dermatol Ges; 2011 Jan; 9(1):54-5. PubMed ID: 21040470
    [No Abstract]   [Full Text] [Related]  

  • 53. Morphea in a Patient With Psoriasis on Treatment With Ustekinumab: Comorbidity or Adverse Effect?
    Corral Magaña O; Escalas Taberner J; Escudero Góngora MM; Giacaman Contreras A
    Actas Dermosifiliogr; 2017 Jun; 108(5):487-489. PubMed ID: 28110825
    [No Abstract]   [Full Text] [Related]  

  • 54. Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review.
    Wilder EG; Patel M; Hebeler K; Menter A
    J Drugs Dermatol; 2014 Aug; 13(8):905-10. PubMed ID: 25116966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eczematous drug eruption after ustekinumab treatment.
    Pernet C; Guillot B; Bessis D
    Arch Dermatol; 2012 Aug; 148(8):959-60. PubMed ID: 22911203
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 57. Fixed drug eruption vs. DLE [proceedings].
    Rupp T
    Int J Dermatol; 1979 Apr; 18(3):243-4. PubMed ID: 156702
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
    Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
    Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
    [No Abstract]   [Full Text] [Related]  

  • 59. Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study.
    Blaszczak AM; Dunaway S; Ali Alikhan M; Kelly S; Levin D; Kaffenberger J
    Int J Dermatol; 2019 Nov; 58(11):e228-e229. PubMed ID: 31334835
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.